No Data
Investors Continue Waiting On Sidelines For Boji Medical Technology Co.,Ltd. (SZSE:300404)
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Boji Medical Technology (300404.SZ): Various departments are researching the application of Deepseek in the company's Operations and Business.
On February 19, Gelonghui reported that Boji Medical Technology (300404.SZ) stated on the investor interaction platform that various departments of the company are researching the application of DeepSeek in the company's Operation and Business. The company continues to pay attention to and actively explore the application of AI technology in new drug research and development to improve the efficiency and quality of new drug development.
Boji Medical Technology Co.,Ltd. (SZSE:300404) Surges 12%; Individual Investors Who Own 55% Shares Profited Along With Insiders
Boji Medical Technology (300404.SZ): Currently, there are no projects related to monkeypox.
According to an investor interaction platform on January 14, Gelonghui reported that Boji Medical Technology (300404.SZ) is a professional CRO service provider, mainly offering pharmaceutical research and development outsourcing services, and currently has no projects related to monkeypox.
Boji Medical Technology (300404.SZ): Received the notice of approval for clinical drug trials.
On December 24, Gelonghui reported that Boji Medical Technology (300404.SZ) announced that the "TBA Tablets" developed in collaboration with Guangdong Gumai Di Health Technology Co., Ltd. has received the "Notice of Approval for Clinical Drug Trials" issued by the National Medical Products Administration. TBA is a new, structurally defined compound with pharmacological effects and clinical value. It is a first-class Innovative Drug that has not been marketed domestically or internationally, with a proposed indication for drug-resistant pulmonary tuberculosis. Tuberculosis is a chronic and deadly infectious disease that is transmitted globally, primarily caused by Mycobacterium tuberculosis. TBA acts on the electron transport of mycobacteria.
Market Cool On Boji Medical Technology Co., Ltd.'s (SZSE:300404) Revenues Pushing Shares 25% Lower
